It might be the latest version of a long-term strategic policy approach, but stakeholders need to ask themselves a critical question. Are they willing to trade a bridging fund and process changes for a few health technologies, based on the promise it could accelerate access, in return for a disinvestment framework and deprioritising most new therapies?
Stakeholders deserve clarity on the strategic objective before this process gets underway
November 25, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Australian medtech secures funds to advance real-time breast cancer surgery technology
February 13, 2026 - - Australian Biotech -
The Dispatched Podcast 'Week in Review' - 13 February
February 13, 2026 - - Podcast -
PBAC to reconsider broader vaccine funding after late addition to March agenda
February 13, 2026 - - Latest News -
Ten years of process 'improvements' is almost the point, says Anne Ruston
February 13, 2026 - - Latest News -
Senate scrutiny of PBS rules after Canberra family highlights lack of biologic access
February 12, 2026 - - Latest News -
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News

